|
| ||
| starting treatment Dec 11, 2011 hi sir i am 35yrs male recently diagnosed+ve.my cd4 is 500.til when approximately i can wait for my treatment to start.i stay in south india.what would be best combination drug to start |
||||||||||
|
|
Response from Dr. McGowan
Hi from America! Right now your CD4 count is quite good. In the US, we currently recommend starting treatment when the CD4 count is at 500 or less, so this would be a good time. If you have access to treatment and can stay on it without interruption (that will lead to the best long-term benefit) then you could start at any time now. Current WHO guidelines recommend starting treatment before the CD4 drops below 350. There are several good combinations. We generally base treatment on 2 NRTIs (nucleoside reverse transcriptase inhibitors), such as the combination tablet tenofovir + emtricitabine with either a NNRTI (non-nucleoside reverse transciptase inhibitor), such as efavirenz (in your case you should not start with the alternate NNRTI, nevirapine, since your CD4 count is above 400 and this drug can cause serious side effects if started with a high CD4 count), or a Protease Inhibitor combination such as ritonavir + atazanavir or darunavir or the combination tablet of ritonavir/lopinavir. These are all well tolerated over time, but you should have your liver and kidney function monitored while on treatment. Best, Joe | |||||||||
Get Email Notifications When This Forum Updates or Subscribe With RSS
|
||||||||||
Q&A TERMS OF USE
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.
Review our complete terms of use and copyright notice.










